Immunotherapy toxicity survey

UCLH cancer academy has been funded to develop multidisciplinary education on check point inhibitors and immune related adverse events.  We are very keen that the materials we produced are helpful to the whole BOPA membership.  To understand where the gaps are we have developed a questionnaire (see link below).  It will take less than 10 minutes to complete and will be really helpful for us to understand where the gaps are at different hospitals.  Please could this be completed by June 2nd.  If you have any questions or would like to keep in touch with our work, then please email Elly on [email protected].

https://forms.office.com/e/rAAj4DzjNK

Latest News

By BOPA Executive Committee on 29th July 2026

Publication ALERT – Managing aseptic capacity pressures in systemic anti-cancer therapy services: A national mixed-methods evaluation of UK SACT board guidance implementation

BOPA Publication: Managing aseptic capacity pressures in systemic anti-cancer therapy services: A national mixed-methods evaluation of UK SACT board guidance implementation – Annette (Netty) Cracknell, Dharmisha Chauhan, Lisa Barrott, Emma…

Read article
By BOPA on 24th July 2026

Call for BOPA Award nominations – 1 week left!

It’s awards time – call for nominations! We have had lots of positive feedback from the introduction of the awards dinner at the annual conference, and we are now calling…

Read article
By BOPA Research Subcommittee on 14th July 2026

Record Abstract Submission for BOPA Annual Conference 2026

BOPA is thrilled to announce that we have received an incredible number of 235 abstracts for our annual conference 2026. The record number of abstract is testament to our continued…

Read article
By BOPA on 12th July 2026

Closing this week – The BOPA Training and Development Grant for BOPA Conference 2026

BOPA are offering (in collaboration with Gilead) 16 funded places to the BOPA 2026 Conference in London from 2-4th Oct 20265. Information can be found here – The BOPA Training and Development Grant…

Read article